Medicare beneficiaries who spend heavily on prescription drugs will see their annual out-of-pocket costs capped at $2,400 starting in plan year 2027. The Centers for Medicare and Medicaid Services finalized the threshold as part of a broader Part D redesign that eliminates the old coverage gap phase and restructures catastrophic cost-sharing. With drug plans already preparing their 2027 bids and open enrollment approaching later this year, the cap will reshape how millions of enrollees and their insurers split the cost of expensive medications.
How the $2,400 cap changes Part D drug spending for enrollees
The $2,400 figure is not a rough target. CMS locked it in as a formal parameter in the 2027 rate guidance, which sets the financial architecture that every Part D plan must follow. Before this redesign, beneficiaries who passed through the initial coverage phase entered a coverage gap where they bore a larger share of drug costs, then eventually reached catastrophic coverage with its own cost-sharing rules. The 2027 structure collapses those layers. Once a beneficiary’s true out-of-pocket spending hits $2,400 in a plan year, the plan and the federal government absorb the rest.
That structural change matters most for people taking high-cost specialty drugs for conditions like cancer, hepatitis C, or autoimmune disorders. Under the old design, a single specialty prescription could push a beneficiary deep into the coverage gap within the first few months of the year. The hard cap at $2,400 gives those enrollees a predictable ceiling, but it also transfers significant financial risk onto plans and manufacturers. The question is how plans will respond to that shifted burden when they set premiums, design formularies, and negotiate rebates for 2027.
For beneficiaries with more modest drug needs, the impact will be subtler. Many enrollees never approached catastrophic coverage under the prior rules, so their annual spending may not change dramatically. Still, the simplified two-stage design-an initial coverage period followed by a firm limit-could make plan materials easier to explain and compare, especially for people who struggled to understand the old “donut hole” terminology. Consumer advocates are watching to see whether clearer benefit structures translate into better plan choices and fewer surprises at the pharmacy counter.
Regulatory record behind the Part D redesign
CMS built the $2,400 threshold into a final rule published in the Federal Register that covers contract year 2027 policy and technical changes to Medicare Advantage, Part D, and Medicare Cost Plan programs. The public inspection version of that regulation, posted as the contract year 2027 policy update, details how the new benefit is structured and how plans must account for the cap in their bids. That rule formally eliminates the coverage gap phase and revises catastrophic cost-sharing, creating a two-stage benefit: an initial coverage period followed by a hard out-of-pocket limit.
In a separate announcement, CMS framed the redesign as part of a broader effort to strengthen oversight of private plans. The agency’s payment policy statement for 2027 emphasizes accountability and long-term sustainability, signaling that regulators see the out-of-pocket cap not only as a consumer protection but also as a lever to rebalance financial responsibility between beneficiaries, plans, manufacturers, and the federal government.
The same $2,400 parameter also appears in the Retiree Drug Subsidy program’s updated cost threshold and cost limit amounts for plan years ending in 2027. Employer and union plans that receive the federal retiree drug subsidy must align their benefit designs with the new figures. That parallel update means the cap’s effects will extend beyond traditional Part D standalone plans and Medicare Advantage prescription drug plans to reach employer-sponsored retiree coverage as well.
Open questions about formulary shifts and premium effects
The regulatory text establishes the $2,400 ceiling but does not publish projections on how individual plans will absorb the added cost. CMS has not released beneficiary-level savings estimates or distributional tables showing which enrollees are most likely to hit the cap. Without that data, it is difficult to gauge how much relief will flow to different groups, such as low-income beneficiaries versus middle-income retirees with multiple chronic conditions.
Insurers, meanwhile, must decide how much of the new liability to build into premiums and how much to manage through tighter utilization controls. Plans have tools-such as prior authorization, step therapy, and tiered formularies-to steer use toward lower-cost alternatives when they exist. As the cap shifts more high-cost claims onto plans, those tools could become more prominent in 2027 benefit designs, potentially affecting access for patients who rely on specific brand-name therapies.
Premiums for 2027 will not be finalized until bids are submitted and reviewed, so there is no public data yet on how the cap will translate into monthly costs. Some beneficiaries may prefer slightly higher premiums in exchange for the certainty of a $2,400 annual maximum, while others who rarely use prescriptions may be more sensitive to even modest increases. The redesigned structure also changes the incentives for manufacturers, who may face different rebate dynamics when plans are responsible for a larger share of spending above the cap.
For now, the clearest takeaway is that the 2027 Part D benefit will be simpler to describe: enrollees pay cost sharing during an initial phase, and once their true out-of-pocket spending reaches $2,400, they are done for the year. How that simplicity plays out in practice-for premiums, access to specific drugs, and the overall stability of the program-will depend on choices that plans, employers, and manufacturers make over the coming months as they adapt to the new rules.
